{"entity":{"id":"exai-oncrna-prospective","kind":"trial","name":"Exai oncRNA prospective study by cancer size and stage","aka":[],"tldr":"Exai Bio's study of a blood test that looks for small RNA molecules made by tumours.","summary":"Exai oncRNA prospective study by cancer size and stage (NCT05833360) is an observational study sponsored by Exai Bio Inc. It develops and evaluates the Exai oncRNA blood test for cancer detection, stratified by tumour size and stage.\n\nThe registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,400 participants, a start on 14 July 2023 and primary completion expected on 14 July 2030.","status":"recruiting","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT05833360","url":"https://clinicaltrials.gov/study/NCT05833360"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy","rna-seq"],"targets":[],"drugs":[],"companies":["exai-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05833360","phase":"observational","setting":"People with and without cancer at US sites, testing a blood test based on orphan non-coding RNAs","sponsor":"Exai Bio Inc.","started":"2023-07-14","startedType":"actual","enrolled":2400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/exai-oncrna-prospective/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"company":[{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/"}]}}